['diffuse large b-cell lymphoma']
['rituximab', 'doxorubicin', 'vincristine', 'cyclophosphamide', 'prednisone']

        Inclusion Criteria:

          1. Patients with histological confirmed CD20 (cluster of differentiation 20) positive
             diffuse large B cell lymphoma (DLBCL)

          2. Patients that had been diagnosed according to the WHO classification;

          3. Performance status ≤ 2 on the ECOG (Eastern Cooperative Oncology Group) / WHO (world
             Health Organization) scale, performance status of 3 will be accepted if impairment is
             caused by DLBCL complications and improvement is expected once therapy is initiated;

        Exclusion Criteria:

          1. Life expectance less than 6 months;

          2. Any chemotherapy, radiotherapy, immunotherapy, biologic, investigational or hormonal
             therapy for treatment of lymphoma within 28 days prior to treatment;

          3. Rituximab, other anti-CD20 mAb (Monoclonal Antibodies) drug treatment, treatment with
             any cell depleting therapies - e.g., anti-CD4 (cluster of differentiation 4) anti-CD5
             (cluster of differentiation 5), anti-CD3 (cluster of differentiation 3), anti-CD19
             (cluster of differentiation 19), anti CD11 (cluster of differentiation 11), anti-CD22
             (cluster of differentiation 11), BLys/BAFF (B Lymphocyte Stimulator/B-cell activating
             factor) within 1,5 years before screening;
      